Fox Chase Cancer Center

Institute for Cancer Research

Immunome, Inc.

Matthew K Robinson

Gregory P Adams

Roland L Dunbrack

Heidi H Simmons

Ray Howanski

Michael John Morin

Andreas Lehmann

John P Dowling

Jared Adolf-Bryfogle

Jillian Dimuzio

Pavel Nikitin

Provided herein are antibodies that are useful for treating SARS-CoV-2 infections in a subject. Also provided herein are compositions comprising one or more antibodies, methods of treatment comprising administering one or more antibodies, and kits comprising one or more antibodies.

Antibody cocktail against SARS-CoV-2 spike protein

Recombinant proteins that comprise a bone morphogenic protein 2 backbone onto which was grafted a M&#xfc;llerian-inhibiting substance type II receptor binding region of the M&#xfc;llerian-inhibiting substance protein are provided. These proteins bind to this receptor on the surface of epithelial cancer cells, and induce apoptosis of such cells. These proteins are useful, for example, in the treatment of cancers such as ovarian, uterine, endometrial, fallopian tube, breast, prostate, and lung cancers.

Chimera of bone morphogenic protein 2 and the M&#xfc;llerian-inhibiting substance type II receptor binding region of M&#xfc;llerian-inhibiting substance

Methods for generating hybrid antibodies are provided.

Rationally-designed anti-mullerian inhibiting substance type II receptor antibodies

Growing community of inventors

Blue Bell, PA, United States of America

Matthew K Robinson